[HTML][HTML] SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies
Monoclonal antibodies (mAbs) offer a treatment option for individuals with severe COVID-19
and are especially important in high-risk individuals where vaccination is not an option …
and are especially important in high-risk individuals where vaccination is not an option …
[HTML][HTML] Evolution of the SARS-CoV-2 Omicron spike
RJ Parsons, P Acharya - Cell reports, 2023 - cell.com
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of
concern, first identified in November 2021, rapidly spread worldwide and diversified into …
concern, first identified in November 2021, rapidly spread worldwide and diversified into …
[HTML][HTML] Monoclonal antibody levels and protection from COVID-19
Multiple monoclonal antibodies have been shown to be effective for both prophylaxis and
therapy for SARS-CoV-2 infection. Here we aggregate data from randomized controlled …
therapy for SARS-CoV-2 infection. Here we aggregate data from randomized controlled …
Evolving real-world effectiveness of monoclonal antibodies for treatment of COVID-19: a cohort study
KE Kip, EK McCreary, K Collins, TE Minnier… - Annals of Internal …, 2023 - acpjournals.org
Background: Treatment guidelines and US Food and Drug Administration emergency use
authorizations (EUAs) of monoclonal antibodies (mAbs) for treatment of high-risk outpatients …
authorizations (EUAs) of monoclonal antibodies (mAbs) for treatment of high-risk outpatients …
Efficacy and safety of tixagevimab‐cilgavimab as pre‐exposure prophylaxis for COVID‐19: a systematic review and meta‐analysis
Some proportions of populations, such as immunocompromised patients and organ
transplant recipients might have inadequate immune responses to the vaccine for …
transplant recipients might have inadequate immune responses to the vaccine for …
[HTML][HTML] Determinants of passive antibody efficacy in SARS-CoV-2 infection: a systematic review and meta-analysis
Background Randomised controlled trials of passive antibodies as treatment and
prophylaxis for COVID-19 have reported variable efficacy. However, the determinants of …
prophylaxis for COVID-19 have reported variable efficacy. However, the determinants of …
[HTML][HTML] Efficacy analysis and research progress of complementary and alternative medicines in the adjuvant treatment of COVID-19
JG Lin, GJ Huang, YC Su - Journal of Biomedical Science, 2023 - Springer
Abstract The coronavirus disease 2019 (COVID-19) pandemic has impacted human
lifestyles around the world, causing huge distress in terms of public health systems …
lifestyles around the world, causing huge distress in terms of public health systems …
[HTML][HTML] HIV and COVID-19 co-infection: epidemiology, clinical characteristics, and treatment
D Basoulis, E Mastrogianni, PM Voutsinas… - Viruses, 2023 - mdpi.com
The COVID-19 pandemic has been a global medical emergency with a significant socio-
economic impact. People with HIV (PWH), due to the underlying immunosuppression and …
economic impact. People with HIV (PWH), due to the underlying immunosuppression and …
[HTML][HTML] SARS-CoV-2 neutralizing antibody bebtelovimab–a systematic scoping review and meta-analysis
Introduction The COVID-19 pandemic is a major global public health crisis. More than 2
years into the pandemic, effective therapeutic options remain limited due to rapid viral …
years into the pandemic, effective therapeutic options remain limited due to rapid viral …
[HTML][HTML] Vaccine effectiveness against severe COVID-19 during the Omicron wave in Germany: Results from the COViK study
A Stoliaroff-Pepin, C Peine, T Herath, J Lachmann… - Infection, 2023 - Springer
Purpose COViK, a prospective hospital-based multicenter case-control study in Germany,
aims to assess the effectiveness of COVID-19 vaccines against severe disease. Here, we …
aims to assess the effectiveness of COVID-19 vaccines against severe disease. Here, we …